Knight Therapeutics Inc
(GUD.TO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2014 | |
| Cash Flows From Operating Activities | |
| Depreciation Amortization | 85 |
| Income taxes - deferred | 772 |
| Accounts receivable | -741 |
| Accounts payable and accrued liabilities | 1,644 |
| Other Working Capital | 4,510 |
| Other Operating Activity | -5,468 |
| Operating Cash Flow | $803 |
| Cash Flows From Investing Activities | |
| PPE Investments | -70 |
| Purchase Of Investment | -149,808 |
| Sale Of Investment | 170 |
| Purchase Sale Intangibles | 139,564 |
| Other Investing Activity | 100,623 |
| Investing Cash Flow | $-49,085 |
| Cash Flows From Financing Activities | |
| Debt Issued | 2,500 |
| Debt Repayment | -2,500 |
| Common Stock Issued | 83,066 |
| Common Stock Repurchased | -595 |
| Other Financing Activity | 246,250 |
| Financing Cash Flow | $328,721 |
| Exchange Rate Effect | 3,006 |
| End Cash Position | 283,445 |
| Net Cash Flow | $280,439 |
| Free Cash Flow | |
| Operating Cash Flow | 803 |
| Capital Expenditure | -70 |
| Free Cash Flow | 734 |